Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenlabs EthicaBOM:530697 61 Receivables Turnover is 0.90 as of Jun. 2026. GuruFocus rates BOM:530697 with a GF Score™ of 61/100 and a GF Value™ of ₹32.00 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, Zenlabs Ethica ranks worse than 78.15% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Zenlabs Ethica's Revenue for the
three
months ended in Jun. 2026 was ₹141.8 Mil. Zenlabs Ethica's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹157.0 Mil.
Hence, Zenlabs Ethica's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.90.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Zenlabs Ethica Receivables Turnover Related Terms
Zenlabs Ethica Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Zenlabs Ethica's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530697 vs MCK, COR, CAH: Receivables Turnover Comparison
For the Medical Distribution subindustry, Zenlabs Ethica's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenlabs Ethica Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Zenlabs Ethica's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenlabs Ethica (BOM:530697) has a Receivables Turnover of 0.90 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zenlabs Ethica and its competitors. According to the industry distribution chart, Zenlabs Ethica ranks #93 out of 119 companies in the Medical Distribution industry, placing it in the top 78.2%.
Is Zenlabs Ethica's Receivables Turnover too high?
Zenlabs Ethica's current Receivables Turnover is 0.90. The Medical Distribution industry median Receivables Turnover is 4.90. Zenlabs Ethica's value of 0.90 is 81.6% below this industry median. Based on the distribution chart, Zenlabs Ethica ranks #93 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Zenlabs Ethica has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's Receivables Turnover compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #93 out of 119 companies for Receivables Turnover. This places Zenlabs Ethica in the lower half of its industry. The industry median Receivables Turnover is 4.90. Zenlabs Ethica's value of 0.90 is 81.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.90, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenlabs Ethica's current Receivables Turnover of 0.90 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zenlabs Ethica and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenlabs Ethica's current Receivables Turnover is 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹32.00, compared to a current price of ₹25.30 — trading 20.9% below its estimated fair value. The current Receivables Turnover is 0.90 and 81.6% below the Medical Distribution industry median of 4.90. Zenlabs Ethica's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current Receivables Turnover is 0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?
Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be undervalued.
The current stock price of ₹25.30 is trading 20.9% below its estimated GF Value™ of ₹32.00.
GuruFocus considers Zenlabs Ethica to be Modestly Undervalued.
Key valuation signals for BOM:530697:
Receivables Turnover: 0.90
GF Value™: ₹32.00 vs. price of ₹25.30 (20.9% below fair value)
Industry Position: 81.6% below the Medical Distribution median (#93 of 119)
No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
61GF Score
Get the complete analysis for BOM:530697
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530697 has been successfully added to your 
